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INTRODUCTION: 
Oral disintegrating/Orodispersible Drug Delivery 
systems: 
Development of a formulation involves a great deal of 
study and experimental work to get Optimum results. 
While doing so we have to keep in mind various factors 
like choice of excipients, drug bioavailability, drug 
stability in required dosage form, cost effectiveness, 
manufacturing aspects i.e. scale-up and last but not the 
least we have to consider the patients compliance and 
convenience. 
Fast disintegrating or orodispersible a tablet (ODTs) is one 
such novel approach to increase consumer acceptance by 
virtue of rapid disintegration, self administration without 
water or chewing. This novel type of delivery system 
offers convenience for treatment-resistant   population who 
have difficulty in swallowing unit oral dosage form, 
namely tablets and capsules. These formulations are 
particularly beneficial to pediatric and geriatric patients, 
also during travelling where excess of water is not there. 
1,2
  
These fast disintegrating tablets can also be designed in 
such a way that the drug is absorbed through the buccal 
and esophageal mucosa as the saliva passes into the 
stomach. Due to this the bioavailability of the drug is 
greater than that observed for conventional dosage form.
3,4 
Furthermore, the side effects caused by first pass 
metabolism may be reduced.
5 
Advantages
6-8
 
 Improved patient compliance is the main 
advantage of this dosage form. 
 Rapid onset of action as the tablet disintegrates 
within a matter of seconds. 
 Useful for pediatric, geriatric and psychiatric 
patients. 
 Suitable during traveling where water is may not 
be available. 
 Give accurate dosing as compared to liquids. 
 Ease of Administration to the patients who are 
unable or refuse to swallow solid unit dosage form. 
 Achieve increased bioavailability/rapid absorption 
through pre-gastric absorption ofdrugs from 
mouth, pharynx & oesophagus as saliva passes 
down. 
 The risk of chocking or suffocation during oral 
administration of conventional formulations due to 
physical obstruction is avoided, thus providing 
improved safety. 
Challenges to develop ODT 
 Rapid disintegration of tablet 
 Avoid increase in tablet size 
 Have sufficient mechanical strength 
 Minimum or no residue in mouth 
 Protection from moisture 
 Good package design 
 Compatible with taste masking technology 
Disadvantages 
 Tablets are very fragile and lack physical 
resistance; because the tablets are very porous and 
low compression forces are used to prepare them. 
they cannot be packed in conventional strips or in 
bottles and special packaging is required. 
 Bitter drugs have to be taste masked by various 
techniques which in turn increases the time and 
cost of production. 
 Drugs to be absorbed at a particular site cannot be 
given in this dosage form. 
Ideal Characteristics of Orodispersible Tablets
9,10
 
ABSTRACT: 
Labetalol HCl competitively blocks adrenergic stimulation of β-receptors within the myocardium (β1-receptors) and within 
bronchial and vascular smooth muscle (β2-receptors), and α1-receptors within vascular smooth muscle. Mouth dissolving drug 
delivery systems (MDTs) have acquired an important position in the market by overcoming previously encountered 
administration problems and contributing to extension of patent life. MDTs have the unique property of rapidly disintegrating 
and/or dissolving and releasing the drug as soon as they come in contact with saliva, thus obviating the requirement of water 
during administration. Taste masking was done by using Kyron-T 134 in ratio 1:3. The tablets were prepared by using direct 
compression method, using different Superdisintegrantsand they were then evaluated for pre and post compression parameters. 
More than 80% of drug was released from almost all the formulations within 5 min. Results of this study indicate among the 
superdisintegrants tried, Indion-414 showed the best result in 2% concentration. 
Key words: Orodispersible Drug Delivery systems, Hypertensive crisis, Tablets. 
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 Not require water for oral administration, yet dissolve 
/ disperse/ disintegrate in mouth in matter of seconds. 
 Have a pleasing mouth feel. 
 Have an acceptable taste masking property. 
 Be harder and less friable. 
 Allow high drug loading 
 Leave minimal or no residue in mouth after 
administration. 
 Exhibit low sensitivity to environmental conditions 
(temperature and humidity). 
Techniques for Preparing Orodispersible Tablets 
US FDA considers fast disintegrating tablets as the new 
dosage form and hence new drug application is required 
for approval. Infact, at present ODTs are quick-dissolving 
dosage form recognized by FDA and listed in Approved 
drug products with therapeutic equivalence evaluation also 
called the orange book.
 
 
 
 
 
                                                                                                                                                                                                                                                                                           
 
 
 
 
 
 
 
Fig. 1:  Various technologies used in the preparation of fast disintegrating orodispersible tablets 
Hypertensive crisis 
Severely elevated blood pressure equal to or greater than a 
systolic 180mmHg or diastolic of 110mmHg  sometime 
termed malignant or accelerated hypertension is referred to 
as a "hypertensive crisis", as blood pressures above these 
levels are known to confer a high risk of complications.  
People with blood pressures in this range may have no 
symptoms. 
A "hypertensive emergency", previously "malignant 
hypertension", is diagnosed when there is evidence of 
direct damage to one or more organs as a result of the 
severely elevated blood pressure. This may include  
 Hypertensive encephalopathy, caused by brain 
swelling and dysfunction, characterized by headaches 
and an altered level of consciousness. 
 Visual deterioration or breathlessness due to heart 
failure  
 General feeling of malaise due to renal failure. 
MATERIALS: 
Labetalol Hcl (Dahlia pharmaceuticals pvt ltd, 
Ahemdabad), Kyron  T-134 and Kyron T-154 (Corel 
pharma, Ahemdabad), Mannitol and Sodium starch 
glycolate (Rajesh chemicals), β-cyclodextrin (Research lab 
fine chem industries, Mumbai), Sorbitol and Sucrose 
(Kashyap sweetners, Mumbai), Indion-414 (Ion exchange 
india ltd, Mumbai), Cross povidone and Vanillin (Analab 
fine chemicals, Mumbai), Cross carmellose sodium (Seva 
fine chemicals, Ahemadabad), Aspartame (Balaji drugs). 
METHOD: 
Selection of taste masking material: 
Preliminary study on various taste masking materials were 
carried out to select the taste masking agent like mannitol, 
sucrose, sorbitol, β-cyclodextrin, ion exchange resins such 
as Kyron –T 134, Kyron T-154 etc,  
Procedure:  
The drug and Kyron T-134 was taken in different ratios 
like 1:1, 1:2, 1:3, 1:4 etc. in this method the resin was 
properly weighed and taken in 40 ml of  water and stirred 
for half an hour on magnetic stirrer so that resin swells. 
Then the Drug was added according to ratio and stirred for 
45 hours continuously on magnetic stirrer. The solution 
was filtered and resinate was washed with water and dried. 
This complex was further used in ODT preparation
. 
 
 
 
 
Techniques 
 
1. Conventional Technology 
 Freeze Drying 
 Tablet Molding 
 Direct Compression 
 Spray Drying 
 Sublimation 
 Mass Extrusion 
 
2. Patented Technology 
 Zydis Technology 
 Orasolv Technology 
 Durasolv Technology 
 Wowtab Technology 
 Flashdose Technology 
 Flastab Technology 
 Oraquick Technology  
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Table 1: list of taste masking agents used with its ratios 
Category Masking agents Ratio of drug:masking agents 
Sugars 
Mannitol 
1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7 
 
Sorbitol 1:1, 1:2, 1:3, 1:4, 1:5 
Sucrose 1:1, 1:2, 1:3, 1:4, 1:5 
Polymeric materials β-cyclodextrin 1:2, 1:3, 1:4, 1:5 
Ion exchange resins 
Indion 234 1:2 
Kyron T-134 
1:1 
1:2 
1:3 
1:4 
Kyron T-154 
1:1 
1:2 
1:3 
1:4 
 
Procedure for preparation of Labetalol HCl ODT: 
Labetalol HCl ODT was prepared by direct compression 
method. All the ingredients were weighed on analytical 
balance and mixed, the taste masked drug was weighed 
and added in the above mixture ensure proper mixing of all 
the ingredients. The tablets were compressed using 8mm 
punch curve shaped using geometric addition method. 
 
Table 2: Formulae for ODT 
Ingredients F0 F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12 
Labetalol HCl 50 50 50 50 50 50 50 50 50 50 50 50 50 
Kyron-T-134 150 150 150 150 150 150 150 150 150 150 150 150 150 
Sodium starch 
glycolate 
- 6 9 12 - - - - - - - - - 
Cross 
carmellose 
sodium 
- - - - 3 6 9 - - - - - - 
Cross 
povidone 
- - - - - - - 6 9 12 - - - 
Indion-414 - - - - - - - - - - 1.5 3 6 
Aspartame 10 10 10 10 10 10 10 10 10 10 10 10 10 
Mg stearate 6 6 6 6 6 6 6 6 6 6 6 6 6 
Talc 6 6 6 6 6 6 6 6 6 6 6 6 6 
Vanillin 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 
Mannitol 76.5 70.5 67.5 64.5 73.5 70.5 67.5 70.5 67.5 64.5 75 73.5 70.5 
Total 300 300 300 300 300 300 300 300 300 300 300 300 300 
 
Pre compression evaluation
11
: 
Angle of Repose: 
Angle of repose has been defined as the maximum angle 
possible between the surface of pile of powder and 
horizontal plane. The prepared granules were allowed to 
flow out of the funnel orifice fixed at a height of 2 cm 
from the surface on a plane paper kept on the horizontal 
platform. The gradual addition of the granules from the 
funnel mouth forms a pile of granules at the surface this is 
continued until the pile touches the stem tip of the funnel. 
A rough circle is drawn around the pile base and the radius 
of the granule cone was measured. Angle of repose was 
then calculated with the use of the following formula: 
                                          
tanθ = h / r 
                    Where, θ= angle of repose 
                                 h= height of the pile  
                                 r = average radius of the powder cone 
Bulk Density: 
Bulk density of the granules was determined by pouring 
gently 10g of sample through a glass funnel into a 50ml 
graduated cylinder. The volume occupied by the sample 
was recorded. The bulk density will be calculated as 
follows: 
Bulk Density (g/ml) = Weight of sample in grams 
                                         Volume occupied by the sample 
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Tapped Density: 
10 grams of granule sample was be poured gently through 
a glass funnel into a 50ml graduated cylinder. The cylinder 
will be tapped from height of 2 inches until a constant 
volume will be obtained. Volume occupied by the sample 
after tapping will be recorded and tapped density will be 
calculated as follows: 
Tapped Density (grams/ml) = Weight of sample in grams 
                                          Volume occupied by the sample 
Carr’s Index: 
One of the important measures that can be obtained from 
bulk and tapped density determinations is the percent 
compressibility or the Carr’s index, I, which is determined 
by the following equation, 
I = Tapped Density – Bulk Density 
Tapped Density 
Hausner’s ratio: 
Hausner’s ratio is defined as a ratio of a tapped density to 
bulk density. It is a measure of relative importance of 
interparticulate interactions. A Hausner ratio greater than 
1.25 is considered to be an indication of poor flowability. 
Method 
Tapped density and bulk density were measured and the 
Hausner’s ratio was calculated using the formula, 
                      Hausner’s ratio = tapped density  
                                                    bulk density 
Table 3: Evaluation of granules 
Granules evaluation for flow properties 
Formulation 
Angle of repose 
(n=3) 
Bulk density 
(n=3) 
Tapped density 
(n=3) 
Carr’s index 
(n=3) 
Hausner‘s ratio 
(n=3) 
F1 19.68 ± 0.22 0.648 ± 0.47 0.727 ± 0.91 10.92 1.12 
F2 25.26 ± 0.25 0.582 ± 0.38 0.797 ± 0.67 27.02 1.37 
F3 23.26 ± 0.29 0.638 ± 0.37 0.775 ± 0.96 17.67 1.21 
F4 24.08 ± 0.26 0.618 ± 0.85 0.772 ± 0.67 20 1.25 
F5 29.89 ± 0.18 0.638 ± 0.37 0.785 ± 0.83 18.20 1.22 
F6 21.01 ± 0.2 0.619±0.22 0.725 ± 0.75 14.62 1.17 
F7 27.33 ± 0.77 0.602 ± 0.31 0.762 ± 0.81 21.04 1.26 
F8 26.44 ± 0.9 0.618 ± 0.85 0.772 ± 0.67 20 1.25 
F9 25.29 ± 0.25 0.598 ± 0.42 0.747 ± 0.36 19.89 1.25 
F10 21.42 ± 0.31 0.612 ± 0.25 0.765 ± 0.88 16.83 1.18 
F11 24.08 ± 0.38 0.621 ± 0.54 0.775 ± 0.67 20 1.26 
F12 26.31 ± 0.21 0.632 ± 0.82 0.787 ± 0.92 20 1.28 
 
Post compression Evaluation: 
Weight variation
12
: 
It was performed as per the method given in the Indian 
pharmacopoeia. Tablets were randomly checked to ensure 
that uniform weight tablets were being made. Twenty 
tablets were selected randomly from each formulation, 
weighed individually and the average weight and % 
variation of weight was calculated. 
Friability
12
: 
20 tablets were weighed and placed in the roche friabilator 
test apparatus, the tablets were exposed to rolling and 
repeated shocks, resulting from free falls within the 
apparatus. After 100 evolutions the tablets were de-dusted 
and weighted again. The friability was determined as the 
percentage loss in weight of the tablets. 
 
%friability = 1 -      Weight of tablet after test         X 100                                       
                               Weight of tablet after test 
 
Hardness: 
Hardness was measured using the Monsanto hardness 
tester. Measure the pressure required to break 
diametrically placed matrix tablet, by a coiled spring. 
Dimensions: 
The thickness and diameter of the tablets was determined 
using a vernier caliper. Five tablets from each formulation 
were used and average values were calculated. 
In-vitro Disintegration Studies
12
: 
Tablets areplaced in the disintegration tubes and time 
required for complete disintegration, that is without  
leaving any residues on the screen is recorded as 
disintegration time. In about 6-8 ml of phosphate buffer 
6.8 pH was taken in 10 ml of measuring cylinder .Tablet 
was placed in the cylinder and complete dispersion of 
tablet in the cylinder was recorded as the disintegration 
time.  
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Table 4: Evaluation of tablets 
Formulation 
Weight variation 
(n=3) 
Hardness 
(n=3) 
Diameter 
(n=3) 
Thickness 
(n=3) 
Friability 
(n=3) 
F1 299.8 ± 0.83 3.6 ± 0.28 8 ± 0.02 1.7 ± 0.01 0.24 ± 0.2 
F2 300.1 ± 1.32 3.3 ± 0.57 8 ± 0.05 1.5 ± 0.02 0.83 ± 0.6 
F3 300.4 ± 1.47 3.3 ± 0.57 8 ± 0.04 1.7 ± 0.03 0.22 ± 0.11 
F4 301.0 ± 1.20 3.8 ± 0.28 8 ± 0.05 1.8 ± 0.04 0.31 ± 0.12 
F5 299.8 ± 1.42 4.2 ± 0.28 8 ± 0.03 1.7 ± 0.02 0.72 ± 0.14 
F6 300.3 ± 1.61 3.8 ± 0.28 8 ± 0.04 1.5 ± 0.01 0.64 ± 0.32 
F7 301.3 ± 1.58 3.3 ± 0.57 8 ± 0.00 1.6 ± 0.02 0.55 ± 0.44 
F8 300.3 ± 1.68 3.1 ± 0.66 8 ± 0.02 1.8 ± 0.05 0.33 ± 0.42 
F9 300.1 ± 1.32 3.5 ± 0.56 8 ± 0.05 1.8 ± 0.03 0.62 ± 0.21 
F10 302.4 ± 1.67 3.4 ± 0.19 8 ± 0.03 1.7 ± 0.04 0.53 ± 0.83 
F11 300.6 ± 1.63 4.3 ± 0.76 8 ± 0.04 1.7 ± 0.05 0.41 ± 0.7 
F12 300.7 ± 1.82 3.8 ± 0.59 8 ± 0.02 1.8 ± 0.06 0.82 ± 0.82 
 
Wetting Time:  
A piece of tissue paper folded twice was placed in a small 
Petri dish (ID =6.5 cm) containing 6 ml of simulated saliva 
pH 7.4, a tablet was put on the paper containing amaranth 
powder on the upper surface of the tablet, and the time 
required for formation of pink color was measured as 
wetting time.  
Tablet Assay: 
Ten tablets were accurately weighed and finely powdered. 
A quantity equivalent to 50 mg of Labetalol HCl was 
transferred to a 100 ml volumetric flask. To it, 50 ml of 0.1 
N HCl was added and shaken for 1 hour to dissolve drug. 
The solution was filtered and residue was washed with 25 
ml of 0.1 N HCl. The washing obtained was added to 
initial filtrate and volume was made upto 100 ml with 0.1 
N HCl. From above solution 1 ml of stock solution was 
diluted to 10 ml. The drug content was determined 
spectrophotometrically at 301.5nm. 
 
Table 5: In-vitro Disintegration time, Wetting time and Tablet assay 
Formulation Disintegration time (Sec.) Wetting time (Sec.) Tablet assay 
F1 110 102 87.03 
F2 89 75 93.02 
F3 66 53 91.8 
F4 80 69 94.58 
F5 51 39 91.11 
F6 45 32 96.17 
F7 63 55 92.4 
F8 55 43 98.18 
F9 35 24 95.48 
F10 45 35 96.16 
F11 40 28 93.14 
F12 25 17 99.71 
 
 
Fig. 2: Cumulative disintegration time and wetting time of Orodispersible tablet of formulations 
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Fig. 3: Cumulative percentage drug content for Orodispersible tablet of formulations 
Dissolution Studies: 
Dissolution studies were carried out for all the formulation 
combinations in triplicate, employing USP XXIII paddle 
method (Apparatus 2) using 0.1N HCl, as the dissolution 
medium (500 ml) at 50 rpm and 37 ± 0.5ºC. An aliquot of 
sample was periodically withdrawn at suitable time 
intervals and volume replaced with equivalent amounts of 
fresh dissolution medium. The samples were analyzed 
spectrophotometrically at 301.5nm. 
Dissolution study was carried out in pH 7.4 saliva 
media,using USP Apparatus type-2 (paddle),at 37ºC 
temperature. 
Dissolution profile: - In-vitro dissolution profile of drug 
Labetalol HCl 
 
Table 6: Dissolution profile of all formulations in pH-7.4 saliva media 
Time in 
min 
F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12 
0 0 0 0 0 0 0 0 0 0 0 0 0 
1 0.67 0.83 1.00 0.25 0.42 0.58 2.00 2.33 2.23 1.83 2.00 2.33 
2 1.34 1.84 2.34 0.67 1.25 1.67 3.05 4.77 4.36 3.69 4.27 5.02 
3 2.35 2.53 3.17 1.18 1.77 2.36 4.55 5.89 6.12 5.56 5.76 5.96 
4 2.78 2.89 4.24 1.52 2.62 3.38 5.79 6.34 6.45 6.56 6.07 6.65 
5 3.01 3.12 4.34 1.67 2.78 3.43 5.89 6.45 6.52 6.67 6.78 6.76 
 
 
Fig. 4: Cumulative percentage drugs released from Orodispersible tablet formulations in saliva 
Table 7: Dissolution profile of all formulations in 0.1 N HCl 
Time in 
min 
F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12 
0 0 0 0 0 0 0 0 0 0 0 0 0 
1 25.52 32.56 38.78 14.26 20.49 24.71 29.35 34.58 42.00 42.61 47.25 52.88 
2 43.47 52.80 63.92 24.45 34.77 47.05 59.33 71.06 83.38 67.8 75.70 85.21 
3 51.17 63.61 73.85 32.35 44.57 52.54 71.84 79.26 89.51 78.36 83.55 92.57 
4 54.64 66.96 77.45 36.33 50.61 57.03 76.03 83.69 94.00 84.59 89.80 96.27 
5 57.74 70.92 81.65 40.72 57.49 61.74 81.05 90.14 98.31 91.45 95.69 99.20 
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Fig. 5: Cumulative percentage drugs released from Orodispersible tablet formulations in 0.1 N HCl 
 
RESULT AND DISCUSSION: 
In the present work, ODTs of Labetalol HCl were prepared 
by direct compression technique using super disintegration 
such as Indion 414 to improve the bioavaibility of 
Labetalol HCl. The dispersion time of tablets were reduced 
by superdisintegrantsthat is Indion 414. 
 
The flow property of polymer and drug was good. The 
taste of drug was bitter, so for masking the bitter taste of 
drug Kyron T-134 was used (drug and Kyron T -134 in 
ratio 1:3 respectively) by Ion exchange resins technique in 
which taste of drug was successfully masked. 
Formulated tablets gives satisfactorily result for various 
physico-chemical evalution of tablet dimension, hardness, 
friability, weight variation, in-vitro dispersion time, 
wetting time and drug content. 
The values of standard deviation for average weight and 
drug content of the tablet prepared indicate weight and 
drug content uniformity with in the batches prepared. 
Based on in-vitro disintegration time, formulation F12 
found to be most promising and displayed a dispersion 
time of 25 sec. 
The formulation F12 have displayed good water absorption 
capacity which indicates better and faster swelling ability 
of the disintegration in presence of little amount of water. 
It was observed from the results that Indion414 used 
formulation showed maximum dissolution rate of 99.18%. 
From the present study, it may be concluded that the ODTs 
of Labetalol HCl can be prepared by direct compression 
method using new superdisintegrants Indion 414. 
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